Pharmacotherapies for Retinal Detachment

Ophthalmology. 2016 Jul;123(7):1553-62. doi: 10.1016/j.ophtha.2016.02.040. Epub 2016 Apr 1.

Abstract

Retinal detachment is an important cause of visual loss. Currently, surgical techniques, including vitrectomy, scleral buckle, and pneumatic retinopexy, are the only means to repair retinal detachment and restore vision. However, surgical failure rates may be as high as 20%, and visual outcomes continue to vary secondary to multiple processes, including postoperative cystoid macular edema, epiretinal membrane formation, macular folds, and, ultimately, photoreceptor death. Therefore, pharmacotherapies are being sought to aid the success rates of modern surgical techniques and reduce or slow the degeneration of photoreceptors during retinal detachment. This review discusses potential therapeutic avenues that aid in retinal reattachment, reduce the rate of retinal redetachment by limiting proliferative vitreoretinopathy, and protect against photoreceptor cell death.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Integrin alpha5beta1 / antagonists & inhibitors
  • Neuroprotective Agents / therapeutic use
  • Oxygen Inhalation Therapy
  • Retinal Detachment / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Anti-Inflammatory Agents
  • Enzyme Inhibitors
  • Integrin alpha5beta1
  • Neuroprotective Agents